Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Crucell  /  Sanofi, Sanofi en nog eens Sanofi

Ontvang nu dagelijks onze kooptips!

word abonnee

Crucell« Terug naar discussie overzicht

Sanofi, Sanofi en nog eens Sanofi

785 Posts
Pagina: «« 1 ... 35 36 37 38 39 40 »» | Laatste | Omlaag ↓
  1. forum rang 10 voda 13 december 2010 16:48
    Sanofi Extends Deadline for Genzyme Tender Offer to Jan. 21
    By Meg Tirrell and Albertina Torsoli - Dec 13, 2010 4:41 PM GMT+0100

    Bloomberg) -- Bloomberg's Erik Schatzker reports on the latest breaking news and top stories in today's Business Briefs. (Source: Bloomberg)
    Sanofi-Aventis SA, the French drugmaker making a hostile bid for Genzyme Corp., extended to Jan. 21 the deadline for the U.S. biotechnology company’s shareholders to tender stock.

    The offer of $69 a share, or about $18.5 billion, was set to expire Dec. 10. About 2.2 million shares, or less than a percent of the stock outstanding, were tendered by the deadline, the Paris-based company said in a statement today.

    “This allows for more time to find the right price, and for Genzyme to start opening its doors to Sanofi,” said Eric Le Berrigaud, an analyst at Raymond James in Paris, in a telephone interview today. He has a “buy” recommendation on Sanofi shares.

    Sanofi, France’s largest drugmaker, took its offer for Cambridge, Massachusetts-based Genzyme directly to shareholders on Oct. 4, after the U.S. company’s chief executive officer, Henri Termeer, spurned the bid as too low and refused to negotiate. The offer, made public Aug. 29, undervalues Genzyme’s stable of experimental drugs and ignores expected revenue growth after the company fixed manufacturing flaws that caused drug shortages, Termeer said.

    “The results of the tender offer reported today demonstrate that our shareholders strongly support the view of the board that the Sanofi offer substantially undervalues Genzyme,” Termeer said in a statement today.

    Genzyme Shares

    Genzyme shares have traded above $69 since the offer was made public, suggesting Termeer has shareholders who support his refusal to negotiate with Sanofi at that price.

    “Genzyme values itself much higher than the current offer from Sanofi,” said Michael Obuchowski, chief investment officer at First Empire Asset Management Inc. in Hauppauge, New York, in an interview last month. “And investors value Genzyme higher than the current offer from Sanofi.”

    The U.S. company wants Sanofi to both increase its offer and to make a later payment based on sales goals for its experimental multiple sclerosis drug Campath, three people with direct knowledge of the matter said Dec. 7. Sanofi is unwilling to meet both demands, they said.

    Sanofi’s bankers at Evercore Partners Inc. and JPMorgan Chase & Co. met with Genzyme’s advisers from Credit Suisse Group AG and Goldman Sachs Group Inc. over the past few weeks to discuss the companies’ differing views of Genzyme’s value, the French drugmaker said in a regulatory filing today. They talked about using additional payments based on Campath to help bridge the gap, according to the filing.

    No Information

    Sanofi was given no confidential information on Genzyme and there’s no assurance the talks will continue, according to the filing.

    Sanofi Chief Financial Officer Jerome Contamine told Bloomberg News on Dec. 1 he still considered the $69-a-share bid a “very good price.”

    Genzyme shares rose 59 cents to $70.41 at 10:20 a.m. New York time in Nasdaq Stock Market trading. Sanofi fell 37 cents to 48.94 euros in Paris.

    Sanofi is seeking acquisitions to replace revenue the company is losing as some of its biggest-selling products, such as the blood thinner Plavix and the cancer drug Taxotere, face competition from generic medicines.

    Genzyme’s drugs are less likely to face generic competitors because they’re made from living cells and are harder to copy than pills made from chemicals. The U.S. Food and Drug Administration designated the therapies as orphan drugs because they’re for diseases without other treatment options, giving them more patent protection.

    ‘Opportunistic’

    Sanofi’s $69-a-share offer is “opportunistic and inadequate,” Termeer wrote in a Nov. 8 letter to Sanofi CEO Chris Viehbacher, which was published in today’s filing. “We continue to have the support of our shareholders” and “are open to a transaction that appropriately recognizes Genzyme’s intrinsic value and prospects.”

    The deal would be the biggest hostile takeover in the drug industry since the transaction that created Sanofi-Aventis in 2004, according to Bloomberg data. Sanofi-Synthelabo acquired Aventis for about $64 billion after raising its bid once.

    To contact the reporters on this story: Meg Tirrell in New York at mtirrell@bloomberg.net; Albertina Torsoli in Paris at atorsoli@bloomberg.net.

    To contact the editors responsible for this story: Phil Serafino at pserafino@bloomberg.net; Reg Gale at rgale5@bloomberg.net.
    .
  2. forum rang 10 voda 14 december 2010 17:20
    Patstelling bij overnamegevecht Sanofi-aventis en Genzyme
    14 december 2010, 0:00 uur | FD.nl

    Door: Franka Rolvink

    Aandeelhouders zijn veelal dolblij met een overnamebod op hun bedrijf. Niet zelden zit er een premie in, die ze snelle winst oplevert. Sommige beleggers azen juist op dit verwachte extraatje. Maar als er discussie over die premie is, dan ontstaat er een patstelling.

    Dat is wat er aan de hand is in het overnamegevecht tussen de Franse medicijnproducent Sanofi-aventis, dat een vijandig bod heeft gedaan op zijn Amerikaanse evenknie Genzyme. Het bestuur en de aandeelhouders van Genzyme vinden dat er geen premie in het overnamebod zit dat Sanofi op 4 oktober rechtstreeks aan de aandeelhouders deed, nadat het bestuur het al had afgewezen.

    Met de kennis van nu klopt dit ook. Sinds de $ 69 per aandeel die Sanofi biedt, staat het aandeel boven de $ 70. Maar in de maanden daarvoor had de koers van het aandeel Genzyme het erg moeilijk. Het bedrijf had de productie moeten staken door foute bacteriën in de installaties. De leveringen lagen stil en de koers viel terug. Dat was ook de reden waarom Sanofi op het bedrijf dook.

    etc.

    www.fd.nl/artikel/20938192/pastelling...
  4. forum rang 4 aossa 14 december 2010 17:30
    quote:

    appie-e schreef op 14 december 2010 17:25:

    Zullen ze dan nu op Crucell duiken?
    De kassa puilt uit en de CEO moet een succes boeken nu de overname van Genzyme voor 99,1% is mislukt (uit m'n hoofd heeft Sanofi in 2 maanden slechts 0,9% binnengehaald).
    Ook het korte lijntje naar Mediobanca is opvallend.
    De foute bacteriën zijn er in inderdaad reeds.
    Opvallende gelijkenis, toch...
  6. maxen 14 december 2010 22:17
    quote:

    aossa schreef op 14 december 2010 17:30:

    [...]
    De foute bacteriën zijn er in inderdaad reeds.
    Opvallende gelijkenis, toch...
    Sanofi, Genzyme
    JnJ, Crucell

    next:
    X, Intercell?

    tinyurl.com/2v4mhye
    Intercell shares tumble after product failure

    ...
    The results on this vaccine, which it had been developing with GlaxoSmithKline (GSK.L), had been keenly awaited by investors for clues as to the strength of its vaccine pipeline.

    Intercell, which is the only major independent vaccine maker left in Europe apart from Dutch company Crucell NV (CRCL.AS), brought its first product to market last year, the Ixiaro vaccine against Japanese Encephalitis, distributed by Novartis AG (NOVN.VX).
  7. [verwijderd] 10 januari 2011 15:29
    Genzyme Confirms Talks With Sanofi Over Lemtrada's Value
    Last update: 1/10/2011 8:38:01 AM


    DOW JONES NEWSWIRES
    Genzyme Corp. (GENZ) confirmed Monday that its discussions with French drug giant Sanofi-Aventis SA (SNY, SAN.FR) include the possible use of a contingent value right, a tool used when buyers and sellers can't agree on a purchase price that kicks in after an acquired company meets sales or regulatory targets. Shares climbed 3.2% to $73.65 in premarket trading and have risen by a third in the past 12 months. The Wall Street Journal on Friday reported financial advisers for the two companies are discussing the value of a CVR that would take the total Genzyme offer to around $80 per share from $69 at present if it meets certain milestones, giving the U.S. target a total value of $20.7 billion.

    The latest discussions focus on how to value the potential of Genzyme's multiple sclerosis drug alemtuzumab, which the U.S. biotechnology company plans to brand as Lemtrada. Genzyme cautioned it can offer no assurance that these talks will continue or result in a deal.

    Sanofi has been pursuing Genzyme since last summer and launched a hostile bid that the company has called grossly undervalued. It had refused to engage with Sanofi but softened its stance when other suitors failed to materialize. -By Lauren Pollock, Dow Jones Newswires; 212-416-2356;

    lauren.pollock@dowjones.com (END) Dow Jones Newswires

    January 10, 2011 08:38 ET (13:38 GMT)
  8. [verwijderd] 11 januari 2011 20:07
    Sanofi-Aventis CEO: Talking To Genzyme About Takeover Offer
    Last update: 1/11/2011 1:52:55 PM
    By Peter Loftus
    Of DOW JONES NEWSWIRES

    SAN FRANCISCO (Dow Jones)--Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said Tuesday the drug maker continues to hold talks with Genzyme Corp. (GENZ) regarding Sanofi's takeover offer, but the outcome is uncertain. "The companies are talking together," Viehbacher told investors at the J.P. Morgan healthcare conference here. "We don't know how far we're going to get."

    Paris-based Sanofi confirmed Sunday it was in talks with Genzyme, based in Cambridge, Mass., to structure a potential acquisition so that part of the consideration is determined later based on milestones achieved by a Genzyme drug for multiple sclerosis, which Genzyme plans to market as Lemtrada.

    Sanofi said, however, there was still a significant gap in the terms and conditions of a deal, and no guarantee that one would be finalized. Sanofi previously bid $69 per share for Genzyme, or $18.5 billion, but Genzyme rejected the offer as inadequate.

    A newly structured offer could reportedly value Genzyme at $80 per share if the Lemtrada milestones are achieved.

    -Peter Loftus, Dow Jones Newswires; +1-215-656-8289; peter.loftus@dowjones.com (END)

    Dow Jones Newswires
    January 11, 2011 13:52 ET (18:52 GMT)
  9. forum rang 10 voda 12 januari 2011 20:06
    Three months after Sanofi-Aventis SA took its $18.5 billion Genzyme Corp. bid hostile, the chief executives of both companies say talks are progressing, with a potential special payment tied to the success of a new drug.

    “This is not a war,” Genzyme Chairman and Chief Executive Officer Henri Termeer said in an interview yesterday at the J.P. Morgan Healthcare Conference in San Francisco. At the beginning, “it was a little bit tense. But it never deteriorated; it actually improved. We found a way to talk.”

    As recently as October, the two chiefs were combative in their descriptions of talks. Sanofi said Termeer had “blocked at every turn” efforts to negotiate, in an Oct. 4 statement after the Paris-based drugmaker announced the offer. Genzyme that month called the offer “inadequate and opportunistic.” Now, talks are more cordial, focusing on a so-called contingent value right, or supplemental fee, if Genzyme can market its cancer drug alemtuzumab for a new use in multiple sclerosis.

    “It’s pretty encouraging,” Lionel Melka, co-manager of Paris-based Bernheim, Dreyfus & Co.’s Diva Synergy Fund, an event-driven fund focused on acquisition targets and an owner of Genzyme shares, said in a telephone interview today. “Genzyme is resigned; they don’t really have other options. Sanofi has the financing in place. The discussions are going in the good direction.”

    Termeer, in yesterday’s interview, said that there is value for both sides to do a deal “in a negotiated manner.” A proxy battle, in which Sanofi would aim to replace Genzyme’s board of directors, “is unattractive to everybody,” he said.

    Genzyme Shares

    Genzyme added 4 cents to $72.38 at 11:48 a.m. New York time in Nasdaq Stock Market trading today. The shares have traded above Sanofi’s $69-a-share offer since Sanofi made its bid public in August, and have gained 33 percent since July 22, the last day of trading before the buyout interest was first reported.

    Sanofi rose 1.81 euros, or 3.7 percent, to 51.25 euros in Paris, the biggest gain since May 10.

    Sanofi, France’s largest drugmaker, has made 37 acquisitions in the last five years with an average size of $1.6 billion, according to Bloomberg data. The company is seeking ways to replace revenue it will lose as some of its biggest- selling products, such as the blood thinner Plavix and the cancer drug Taxotere, face competition from generic medicines.

    Living Cells

    Genzyme’s drugs are less likely to face generic competitors because they’re made from living cells and are harder to copy than pills made from chemicals. The U.S. Food and Drug Administration designated the therapies as orphan drugs because they’re for diseases without other treatment options, giving them more patent protection.

    Termeer said yesterday that a special payment plan based on the value of alemtuzumab needs to be negotiated before a sale price is struck with Sanofi, and that $69 a share even with the potential for added payments isn’t enough.

    “We’ve been very clear that $69 is not a starting point, and that’s still the same today,” Termeer said. The $69-a-share bid, even with an added CVR, is “not a starting point” for further discussions, he said. “There is a wish on both sides to understand it -- then we can talk about the broader context.”

    Sanofi went directly to shareholders of the Cambridge, Massachusetts-based biotech with its $69-a-share bid in October after Genzyme rejected the offer as too low. The companies said Jan. 10 that their financial advisers and other representatives from both firms had met to discuss a so-called contingent value right plan, or CVR, related to milestones for Genzyme’s MS drug.

    European Union antitrust regulators today approved the proposed deal. The acquisition wouldn’t harm competition in the 27-nation region, the European Commission said in an e-mailed statement.

    A ‘Deal in the U.S.’

    Sanofi CEO Chris Viehbacher said yesterday at the same conference that expanding in the U.S. is critical.

    “Everyone’s busy talking about India and China, but you can’t write off the United States,” Viehbacher said. “It’s become important for us to do a deal in the U.S. and also to balance out the geographies a bit.”

    Genzyme has projected peak sales of $3.5 billion for alemtuzumab, known as Campath in the blood cancer indication and which would be sold as Lemtrada if approved for multiple sclerosis. Sanofi has cited analysts’ estimates of about $700 million.

    “We’re very focused in discussions around the CVR,” Termeer said in the interview. “So there is progress in that regard.” He said he hasn’t met with Viehbacher specifically about the bid over the past several weeks, though they have discussed other matters.

    During his presentation at the conference, Viehbacher said that he doesn’t know “how far we’ll get” with the takeover attempt. The deal must make sense for shareholders of both companies, he said.

    In the Audience

    Termeer was in the audience for Viehbacher’s presentation, and afterward said in an interview that he believed there could be a fit between the companies.

    “He has a health-care conglomerate, and that’s one way when you are in this business to be able to afford to be an innovator, because he earns money,” Termeer said. “Those earnings can be dedicated to doing truly remarkable things from a health-care contribution point of view, including doing the things that we do.

    “I don’t see a conflict in being a diverse enterprise that earns profits that they can invest in important medical contributions,” he said.

    Sanofi’s proposed acquisition of Genzyme received European Union antitrust

    To contact the reporter on this story: Meg Tirrell in New York at mtirrell@bloomberg.net.

    To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.
  10. [verwijderd] 14 januari 2011 14:59
    The continuing story of......

    Sanofi-Aventis: Position Has Not Changed On Genzyme
    Last update: 1/14/2011 8:28:25 AM

    PARIS (Dow Jones)--French pharmaceutical giant Sanofi-Aventis SA (SNY) Friday declined to comment on whether it plans to increase its $69-a-share offer to acquire U.S. biotechnology group Genzyme Corp. (GENZ) and said its position hasn't changed since Sunday. French national daily newspaper Le Figaro reported earlier in the day that Sanofi-Aventis is hoping to make a successful offer for Genzyme by raising its total bid to $76 a share, or $20.4 billion, representing $70-$71 cash and the rest in later payments if certain performance targets are met.

    "Our position hasn't changed since Sunday," a spokesman for the French drug maker told Dow Jones Newswires, when asked about the veracity of the Le Figaro story. Paris-based Sanofi-Aventis said Sunday it was in talks with Genzyme, based in Cambridge, Mass., to structure a potential acquisition so that part of the financial consideration is determined later, based on targets achieved by a new Genzyme drug for multiple sclerosis which will be marketed under the name Lemtrada.

    Sanofi-Aventis had said, however, there was still a significant gap in the terms and conditions of a deal, and that there is no guarantee an agreement can be finalized. Sanofi-Aventis for some time has been expected to raise its initial $18.5 billion bid that Genzyme rejected as inadequate and hostile.

    The Wall Street Journal Friday reported that financial advisers for the two companies are discussing a structure known as a contingent value right. The valuation of CVR under discussion could take the total Genzyme offer to around $80 per share from $69 at present if it meets certain milestones, giving the U.S. target a total value of $20.7 billion, the paper said.

    The Wall Street Journal is a sister publication of this newswire.

    -By A.H. Mooradian and Angeline Benoit, Dow Jones Newswires; +33 1 4017 1755; art.mooradian@dowjones.com and angeline.benoit@dowjones.com (END) Dow Jones Newswires

    January 14, 2011 08:28 ET (13:28 GMT)
  11. forum rang 10 voda 31 januari 2011 17:48
    'Sanofi en Genzyme hebben deal'
    31 januari 2011, 17:32 | ANP
    BOSTON (AFN) - Biotechnologiebedrijven Sanofi-Aventis en Genzyme zijn het eens over een fusie. Dat meldde persbureau Reuters maandag op basis van twee bronnen bekend met de situatie. De overeenstemming is opmerkelijk, aangezien Genzyme zich van meet af aan heeft verzet tegen een overname.

    Volgens de bronnen is er in de principe-overeenkomst tussen Sanofi en Genzyme een extra recht voor de Genzyme-aandeelhouders opgenomen. Aandeelhouders zou iets extra's tegemoet kunnen zien als het experimentele medicijn Lemtrada (tegen multiple sclerose) bepaalde mijlpalen haalt qua omzet en regelgeving.

  12. [verwijderd] 3 februari 2011 13:12
    Sanofi Could Announce Genzyme Deal Early Next Week- Report

    Last update: 2/3/2011 3:51:09 AM

    PARIS (Dow Jones)--French drug giant Sanofi-Aventis (SNY) could announce a deal to acquire U.S. biotech company Genzyme Corp. (GENZ) early next week, if the final stages of negotiations run without complications, French daily Le Figaro reports Thursday, without citing sources. Sanofi will offer a minimum of $19.3 billion in cash, or around $72 to $73 a share for Genzyme, the paper says. Sanofi's final offer includes a contingent value right--or CVR--linked to the performance of Lemtrada, Genzyme's multiple sclerosis treatment, of $2-$5 a share, according to the paper.

    Newspaper Web site: www.lefigaro.fr -By Paris Bureau, Dow Jones Newswires; 33-1-4017 1740 (END) Dow Jones Newswires

    February 03, 2011 03:51 ET (08:51 GMT)
  13. forum rang 10 voda 7 februari 2011 16:16
    'Sanofi overweegt hoger bod op Genzyme'
    Gepubliceerd op 7 feb 2011 om 11:37 | Views: 137

    Artikel Reacties PARIJS (AFN) - De Franse farmaceut Sanofi-Aventis is bereid het bod op het Amerikaanse biotechnologiebedrijf Genzyme te verhogen. De partijen zouden maandag dichtbij overeenstemming over een overname zijn.

    Sanofi lanceerde vorig jaar een vijandig bod op Genzyme van 69 dollar per aandeel. In januari werd duidelijk dat de partijen constructieve overnamegesprekken voeren.

    Bronnen rond het proces meldden afgelopen weekend dat Sanofi bereid is het bod te verhogen naar 74 dollar. Daarnaast zouden aandeelhouders een extra vergoeding krijgen als het experimentele medicijn tegen multiple sclerose Lemtrada bepaalde doelen haalt. Het bod van 74 dollar waardeert Genzyme op 19,2 miljard dollar (14,1 miljard euro).
  14. [verwijderd] 9 februari 2011 12:56
    Sanofi Still Talking To Genzyme, Sees Lower 2011 Earnings

    Last update: 2/9/2011 3:29:49 AM(Adds details, analyst comment and share reaction.)

    By Mimosa Spencer Of DOW JONES NEWSWIRES


    PARIS (Dow Jones)--French drugs giant Sanofi-Aventis (SNY) Wednesday said talks with its takeover target U.S biotech Genzyme (GENZ) are ongoing, further extending months of suspense surrounding the deal as it forecast an earnings decline this year of between 5%-10%. "We are continuing to review non-public information," after signing a confidentiality agreement with Genzyme around 10 days ago, said Sanofi Chief Executive Chris Viehbacher in an early morning conference call with journalists. Sanofi has been pursuing the U.S. biotech since last summer. The two companies only recently engaged in discussions, after months of disagreeing on the $69-per-share price initially put forward by Sanofi.

    With a likely price tag above the current $18.5 billion tender offer, which expires at midnight on February 15, an eventual deal would be the largest acquisition in a series of smaller deals and partnerships forged under Viehbacher's leadership as the company seeks to bulk up its offer of future products. Like the rest of the industry, Sanofi is struggling to replace lost business as expiring patents leave key drugs open to generic competition.

    Sanofi's business net profit, the term it uses for adjusted income excluding items such as impacts associated with acquisitions, for the last three months of the year was EUR1.84 billion, down 0.3% compared to EUR1.84 billion a year ago. The company said it expects generic competition to accelerate next year and predicts a 5% to 10% decline in 2011 business earnings per share.

    The forecast does not assume a return of generic competition to cancer treatment Eloxatin in the U.S., or any benefit from the possible acquisition of Genzyme, the company said in its only reference to Genzyme in the quarterly earnings statement. The outlook for this year disappointed investors, and at 0810 GMT, Sanofi shares traded down 1.9% or EUR0.99 lower to EUR50.15 underperforming the CAC-40 index, down 0.1%.

    "2011 guidance looks disappointing," especially given that Sanofi expects to realize its EUR2 billion cost savings goal this year, ahead of 2013 as originally planned, said MFGlobal in a research note. Net profit attributable to shareholders was EUR437 million, down 64% from EUR1.21 billion a year earlier. Sales inched up 0.5%, as favorable currency movements during the quarter helped temper the drop in revenue from key drugs including the Taxotere cancer treatment, Plavix anti-blood clotting treatment and Lovenox blood thinner, all hit by generic competition. The foreign exchange boost mostly came from a weaker euro compared to the US dollar, Japanese yen, Brazilian real and Australian dollar.

    Fourth-quarter sales of Lovenox, Taxotere, Plavix were down 27%, 20% and 19% respectively, at constant exchange rates, the company said. Sales by the consumer health care division--one of the units Sanofi is counting on as a future source of growth-- rose 33% to EUR572 million, lifted by acquisitions, including Chattem, which gave the French company a foothold in the U.S. consumer healthcare market.

    Annual sales rose 3.7% to EUR30.38 billion in 2010, the first year that Sanofi felt the painful impact of key medicines losing their patent protection. Net profit attributable to shareholders for the year was up 3.8%, at EUR5.47 billion. Sanofi shares have traded nearly flat over the past three months, underperforming a nearly 5% rise in the Paris CAC-40 index over the same period. Uncertainty over the Genzyme deal has preoccupied investors amid worries the company could overpay for the U.S. target.

    By Mimosa Spencer, Dow Jones Newswires; +33 1 40 17 1773; mimosa.spencer@dowjones.com (END) Dow Jones Newswires

    February 09, 2011 03:29 ET (08:29 GMT)
  15. forum rang 10 voda 9 februari 2011 16:08
    Sanofi praat nog met Genzyme, ziet lagere winst 2011


    AMSTERDAM (Dow Jones)--Sanofi-Aventis sa (SAN.FR) zet de al maanden durende gesprekken met het Amerikaanse biotechbedrijf Genzyme (GENZ) voort en ziet de winst in 2011 zakken met 5% tot 10%, aldus het Franse farmaceutische bedrijf woensdag bij de bekendmaking van de jaarcijfers.

    "We zijn nog niet-publieke informatie aan het beoordelen, nadat tien dagen terug een vertrouwelijkheidsovereenkomst met Genzyme is getekend", aldus chief executive Chris Viehbacher van Sanofi.

    Sanofi zit al sinds afgelopen zomer achter Genzyme aan. Pas recent zijn de twee bedrijven in gesprek gegaan, na maanden te hebben touwgetrokken over een bod door Sanofi van $69 per aandeel.

    Het bedrijf zegt verder te verwachten dat merkloze medicijnen een groter marktaandeel zullen krijgen. Onder meer als gevolg daarvan zal de winst per aandeel met 5% tot 10% dalen in 2011.

    De operationele nettowinst van Sanofi, exclusief posten zoals de kosten voor acquisities, kwam in de laatste drie maanden van het jaar uit op EUR1,84 miljard, 0,3% lager vergeleken met een jaar eerder.

    De nettowinst kwam uit op EUR437 miljoen, tegen EUR1,21 miljard in de vergelijkbare periode een jaar eerder.

    De omzet steeg met 0,5%, terwijl positieve valutaeffecten tegenwicht boden aan lagere verkopen van belangrijke medicijnen als Taxotere, Plavix en Lovenox.

    Het aandeel Sanofi sloot dinsdag op EUR51,14.


    Door Mimosa Spencer; Dow Jones Nieuwsdienst; mimosa.spencer@dowjones.com; +31-20-571 5200


  16. [verwijderd] 16 februari 2011 09:49
    Sanofi koopt Genzyme voor $20 miljard
    16-02-2011 09:37:00
    PARIJS (Dow Jones)--De Franse medicijnproducent Sanofi-Aventis (SNY) heeft woensdag een einde gemaakt aan maanden van onzekerheid, door bekend te maken het Amerikaanse biotechbedrijf Genzyme (GENZ) over te nemen voor $74 per aandeel, of een totaal van $20,1 miljard plus mogelijke successiebetalingen.

    De Raden van Bestuur van beide bedrijven hebben de overname goedgekeurd, aldus Sanofi-Aventis.

    Bovenop de prijs per aandeel ontvangt iedere aandeelhouder een recht op succesiesuitkeringen, die worden uitgekeerd als Genzyme's behandeling van multipele sclerose bepaalde doelen behaalt.

    Sanofi is sinds afgelopen zomer op jacht naar Genzyme. Na maanden van publieke onenigheid over de waarde van Genzyme, en een bod van Sanofi van $69 per aandeel, tekenden de bedrijven begin dit jaar een overeenkomst, waarbij de Franse onderneming toestemming kreeg niet-publieke informatie in te zien.

    Door Mimosa Spencer; Dow Jones Nieuwsdienst; +31-20-5715 210, amsterdam@dowjones.com

  19. forum rang 4 aossa 1 maart 2011 12:32
    Chris Viehbacher (Sanofi-Aventis) haalt met Genzyme zijn gram

    Dat de Franse farmareus Sanofi-Aventis vorige week de hand kon leggen op het Amerikaanse biotechbedrijf Genzyme, is de verdienste van de 50-jarige Duits-Canadese wijnliefhebber Chris Viehbacher.

    Geboren in Canada uit Duitse ouders, heeft Viehbacher beide nationaliteiten. Hij studeerde handelswetenschappen aan de Queens University in Ontario en is een gediplomeerd accountant.

    De vader van drie startte zijn loopbaan bij PriceWaterhouseCoopers en ging in 1988 aan de slag bij de groep Wellcome, als financieel directeur van het Duitse filiaal. Wellcome zou uitgroeien tot GlaxoSmithKline (GSK) via de fusies van Wellcome met Glaxo en later van Glaxo Wellcome met SmithKline Beecham. Na enkele jaren in Canada werd Viehbacher in 1995 verantwoordelijk voor Frankrijk. Hij bleef er negen jaar en kreeg in 2003 zelfs het légion d’honneur, de belangrijkste Franse nationale onderscheiding.

    Ondanks een vlekkeloze carrière van twintig jaar bij GSK greep de razend ambitieuze Viehbacher vorig jaar naast de ultieme bekroning. Als kandidaat-CEO werd hij de loef afgestoken door de Brit Andrew Witty. Nochtans had Viehbacher zich bewezen in complexe dossiers. Zo speelde hij een cruciale rol in de succesvolle integratie van Glaxo met SmithKline, zette hij de overname van Reliant Pharmaceuticals op, en werd hij geroemd voor de expansie van de Noord-Amerikaanse activiteiten. Viehbacher, vloeiend in Frans, Engels en Duits, loodste GSK ook door de crisis met de diabetespil Avandia, na berichten over mogelijke bijwerkingen.

    Een handvol maanden later gaf de temperamentvolle Viehbacher er de brui aan bij GSK. Twee dagen later stapte hij langs de grote poort binnen bij Sanofi-Aventis, ’s werelds vierde grootste farmabedrijf en het nummer één in de eurozone. Hij werd ingehaald als de redder van het bedrijf, dat zelf het product was van de fusie van vijf ondernemingen, inclusief het Duitse Hoechst.

    Viehbacher moest bij Sanofi snel een nieuwe langetermijnstrategie uittekenen. Het bedrijf was er niet in geslaagd voldoende nieuwe geneesmiddelen te ontwikkelen om het omzetverlies door generische concurrentie te compenseren. Ook Plavix, lang ’s werelds tweede best verkochte product, zal klappen krijgen. Die generische dreiging woog zwaar op de aandelenkoers.

    Viehbacher ging in sneltreinvaart aan het werk. Na twee jaar had hij al ruim 40 deals afgesloten, voor hij zijn pijlen richtte op Genzyme, dat in ons land 450 werknemers telt en in Geel een van zijn belangrijkste vestigingen heeft. De sluwe Viehbacher had zijn coup perfect getimed. Genzyme noteerde midden 2008 nog tegen 83 dollar, maar het aandeel werd door productieproblemen in de VS afgestraft en stond net voor de toenadering door Viehbacher slechts op 47 dollar. Viehbacher had bovendien gewacht tot grote broers in de sector - Pfizer, Merck en Roche - hun spaarpot hadden leeggemaakt voor megaovernames. Zo nam Pfizer Wyeth over voor 68 miljard dollar, kocht Merck Schering-Plough voor 47 miljard dollar, en legde Roche 47 miljard op tafel voor Genentech.

    Topman Henri Vermeer, die Genzyme sinds 1983 had uitgebouwd tot ’s werelds grootste producent van biotechnologiemedicijnen tegen zeldzame ziektes, had gegokt op een biedstrijd die de overnameprijs nog fors zou opdrijven. Maar Viehbacher bleek de betere pokerspeler: naarmate de tijd vorderde en er geen witte ridder kwam opdagen, won hij de steun van steeds meer aandeelhouders van Genzyme. De concurrentie leek “bezig te zijn met andere dingen”, blikt Viehbacher terug. “We waren niet verrast dat geen andere bieder kwam opdagen.”

    Vorige week werd de Genzyme-deal voor 20 miljard dollar beklonken, de eerste grote triomf voor Viehbacher, die lid is van diverse ngo’s. Welingelichte bronnen fluisteren trouwens dat hij niet enkel door commerciële overwegingen werd gedreven naar Genzyme. “Hij heeft humanitaire kwaliteiten, een persoonlijke interesse in kanker en in onderzoek in het algemeen”, klinkt het. Viehbacher is bovendien hondenliefhebber, en vooral ook verlekkerd op prestigieuze Bordeaux-wijnen. Niet verwonderlijk dat het dossier Genzyme ‘Grand Cru’ heette. Sanofi kreeg de codenaam Petrus, en Genzyme was Margaux.

785 Posts
Pagina: «« 1 ... 35 36 37 38 39 40 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 878,83 -0,39%
EUR/USD 1,0683 +0,12%
FTSE 100 8.132,36 -0,14%
Germany40^ 17.905,20 -1,18%
Gold spot 2.304,54 -1,34%
NY-Nasdaq Composite 15.657,82 -2,04%

Stijgers

Corbion
+2,70%
B&S Gr...
+1,20%
Ahold ...
+1,17%
ForFar...
+1,04%
OCI
+1,00%

Dalers

VIVORY...
-13,94%
EBUSCO...
-5,50%
ACOMO
-4,69%
Air Fr...
-4,29%
Arcadis
-3,88%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!